THAR: מכפיל מחיר לרווח לצמיחה tharimmune.com
The implementation of energy-efficient systems and strict waste control support the current trend, with the latest parameter standing at 0.00. The P/E ratio and EPS growth correlation help identify the asset's undervaluation. Tharimmune, Inc. (THAR) business development remains independent of GDP phases, relying instead on clinical successes, while expansion potential is based on securing major institutional partners for joint drug trials.
Tharimmune, Inc. (THAR) - פילוחי מדדים ודוחות פיננסיים
The PEG ratio assesses the fairness of an asset's market value by relating the P/E multiple to earnings growth rates. By analyzing P/E dynamics relative to profit growth, an investor determines the degree of a company's undervaluation. A value below one signals growth potential that exceeds the current share price. For Tharimmune, Inc. (THAR), this indicator is critical due to high capital burn during early-stage trials. The metric allows for balancing pre-commercial period risks against future expansion rates.
